Edition:
India

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

87.72USD
10:57pm IST
Change (% chg)

$3.67 (+4.37%)
Prev Close
$84.05
Open
$86.75
Day's High
$88.30
Day's Low
$85.24
Volume
253,648
Avg. Vol
270,563
52-wk High
$163.33
52-wk Low
$71.42

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb And Bluebird therapy for multiple myeloma succeeds in mid-stage trial
Saturday, 7 Dec 2019 

Dec 6 (Reuters) - bluebird bio Inc ::BRISTOL-MYERS SQUIBB AND BLUEBIRD BIO ANNOUNCE POSITIVE TOP-LINE RESULTS FROM THE PIVOTAL PHASE 2 KARMMA STUDY OF IDE-CEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA.BRISTOL-MYERS SQUIBB CO - STUDY MET ITS PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINT.BRISTOL-MYERS SQUIBB CO - STUDY'S SAFETY RESULTS ARE CONSISTENT WITH DATA PRESENTED IN CRB-401 STUDY.  Full Article

Bluebird Bio Inc Reports Q3 Loss Per Share Of $3.73
Friday, 1 Nov 2019 

Oct 31 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.ENDED QUARTER WITH $1.41 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.JEFFREY T. WALSH, CHIEF STRATEGY OFFICER, HAS DECIDED TO TRANSITION FROM HIS CURRENT ROLE EFFECTIVE JANUARY 6.QTRLY COLLABORATION AND LICENSE AND ROYALTY REVENUES WERE $8.9 MILLION VERSUS $11.5 MILLION.QTRLY NET LOSS WAS $206.0 MILLION VERSUS $145.5 MILLION.QTRLY LOSS PER SHARE $3.73.Q3 EARNINGS PER SHARE VIEW $-3.52, REVENUE VIEW $10.8 MILLION -- REFINITIV IBES DATA.  Full Article

Bluebird Bio Announces EU Conditional Marketing Authorization For Zynteglo
Monday, 3 Jun 2019 

June 3 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO ANNOUNCES EU CONDITIONAL MARKETING AUTHORIZATION FOR ZYNTEGLO™ (AUTOLOGOUS CD34+ CELLS ENCODING ΒA-T87Q-GLOBIN GENE) GENE THERAPY FOR PATIENTS 12 YEARS AND OLDER WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA WHO DO NOT HAVE Β0/Β0 GENOTYPE.WILL CONTINUE COUNTRY-BY-COUNTRY REIMBURSEMENT PROCESS TO HELP ENSURE ACCESS TO ZYNTEGLO FOR APPROPRIATE PATIENTS.  Full Article

Bluebird Bio QTRLY Net Loss Per Share $2.99
Friday, 3 May 2019 

May 2 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q1 REVENUE $12.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.2 MILLION.ENDED QUARTER WITH $1.73 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.QTRLY NET LOSS PER SHARE $2.99.Q1 EARNINGS PER SHARE VIEW $-2.80, REVENUE VIEW $13.2 MILLION -- REFINITIV IBES DATA.  Full Article

EU Medicines Agency Panel Recommends Conditional Approval Of Bluebird Bio's Zynteglo
Friday, 29 Mar 2019 

March 29 (Reuters) - European Medicines Agency::EU MEDICINES AGENCY PANEL RECOMMENDS APPROVAL OF BLUEBIRD BIO’S GENE THERAPY ZYNTEGLO FOR TREATMENT OF A TYPE OF BLOOD DISORDER WITH CONDITIONS.  Full Article

Bluebird Bio Reports Fourth Quarter And Full Year 2018 Financial Results And Highlights Operational Progress
Friday, 22 Feb 2019 

Feb 21 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $19.2 MILLION VERSUS $4.2 MILLION.Q4 REVENUE ESTIMATE $8.1 MILLION -- REFINITIV IBES DATA.QTRLY LOSS PER SHARE $2.72.Q4 EARNINGS PER SHARE VIEW $-2.86 -- REFINITIV IBES DATA.  Full Article

Bluebird Bio Appoints Chip Baird From Amicus Therapeutics As CFO
Monday, 11 Feb 2019 

Feb 11 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO APPOINTS CHIP BAIRD AS CHIEF FINANCIAL OFFICER.BLUEBIRD BIO INC - JEFF WALSH TO ASSUME ROLE OF CHIEF STRATEGY OFFICER.BLUEBIRD BIO INC - JASON COLE TO ASSUME ROLE OF CHIEF OPERATING AND LEGAL OFFICER.BLUEBIRD BIO INC - BAIRD JOINS BLUEBIRD FROM AMICUS THERAPEUTICS.  Full Article

Bluebird Bio Q3 Revenue $11.5 Million
Friday, 2 Nov 2018 

Nov 1 (Reuters) - bluebird bio Inc ::BLUEBIRD BIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q3 REVENUE $11.5 MILLION VERSUS $7.7 MILLION.Q3 REVENUE VIEW $7.5 MILLION -- THOMSON REUTERS I/B/E/S.ENDED QUARTER WITH $2.0 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES.ANTICIPATES THAT ITS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL BE SUFFICIENT TO FUND OPERATIONS INTO 2022.QTRLY LOSS PER SHARE $2.73.COMPANY PLANS TO PURSUE ACCELERATED DEVELOPMENT PATHWAY FOR LENTIGLOBIN(TM) IN SICKLE CELL DISEASE (SCD).Q3 EARNINGS PER SHARE VIEW $-2.84 -- THOMSON REUTERS I/B/E/S.  Full Article

Bluebird Bio Reports Q4 Loss Per Share $2.52‍​
Thursday, 22 Feb 2018 

Feb 21 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS.Q4 REVENUE $4.2 MILLION VERSUS $1.6 MILLION.‍ENDED YEAR WITH $1.6 BILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.QTRLY LOSS PER SHARE $2.52‍​.  Full Article

Bluebird Bio Expects Three Regulatory Filings By End 2019
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Bluebird Bio Inc ::BLUEBIRD BIO CEO SAYS EXPECTS THREE REGULATORY FILINGS BY END 2019.BLUEBIRD SEES FILING FOR APPROVAL IN BETA THALASSEMIA IN 2018.BLUEBIRD BIO SEES FILING FOR US AND EU APPROVAL OF B2121 FOR MULTIPLE MYELOMA IN 2019.  Full Article

Photo

Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study

Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments.